The University of Virginia is participating a clinical research study for adults ages 18 and over, who have advanced cancer. The main purpose of this study is to evaluate whether NX-1607, an oral study drug, is safe and tolerated, and to identify the highest dose that can safely be given. Another main purpose of this study is to evaluate whether NX-1607 has an effect on the cancers being studied.
The study is expected to last for about four years. How long you participate in this study depends on how your cancer responds to the study drug. It also depends on whether you have side effects to the study drug that make you want to stop receiving it.
Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.
Additional information can be found here: https://clinicaltrials.gov/ct2/show/NCT05107674